Solvay Pharmaceuticals signs additional agreement to get maximum global expansion for Androgel


Solvay Pharmaceuticals announced the signing of additional agreements for important geographical expansions to one of its top selling products AndroGel® with the pharmaceutical company Besins International. AndroGel® is used in Testosterone Replacement Therapy (TRT) and one of Solvay's solid performers; according to Solvay in 2005 sales exceeded EUR 235 million Euro in the USA, Canada and Germany.

Solvay Pharmaceuticals now acquires exclusive distribution rights for Latin America (including Brazil and Argentina), for several countries in Asia and for all African countries. Semi-exclusive rights are now acquired for five additional European countries (France, Belgium, UK, Spain, Greece).

Other news from the department research and development

Most read news

More news from our other portals

Is artificial intelligence revolutionising chemistry?